
LogicBio Therapeutics Net Debt | LOGC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -47.2 M | -60.9 M | -22.8 M | -80.9 M | -24.6 M | -1.73 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.73 M | -80.9 M | -39.7 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
-136 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
-81 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-3.5 M | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-1.97 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-9.68 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-64.8 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-34.5 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-119 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
1.5 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-34.8 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-990 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-398 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-11.5 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-278 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-4.07 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
-36.8 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-260 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-11.1 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
7.16 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
489 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-1.98 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-33.5 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-4.65 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
-114 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-236 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-29.4 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-2.42 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-45.8 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-6.03 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-25.6 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
-37.5 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
-141 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-53 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
14.7 B | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
-55.8 M | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
-65.3 M | - | - | $ 2.02 B | ||
|
Turning Point Therapeutics
TPTX
|
-422 M | - | -0.13 % | $ 3.73 B | ||
|
Orgenesis
ORGS
|
157 K | - | -33.86 % | $ 61.2 M | ||
|
TCR2 Therapeutics
TCRR
|
-7.6 M | - | - | $ 58.1 M |